Critical patients with high hs-cTnI (>28 pg/mL) levels were more likely to die [27] (2.637 times more likely, 95% CI, 1.058-6.570, p = 0.037)) than those with low levels, as well, hs-cTnI was an independent risk factor of mortality [27] in these patients, which indicates that hs-cTnI levels may be useful in assessing mortality risk in critically ill patients with COVID-19. Here, TNNI3 is linked to COVID-19.